Aptabio's Aptazyme Achieves First Primary Endpoint in Global Phase 2 Trial
Predicted impact: Medium· Actual: −7.4% vs sector, volume 1.1× normal (5 trading days)
Global Phase 2 primary endpoint met; meaningful clinical milestone for a small biotech.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.